Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Casdozokitug by Coherus BioSciences for Renal Cell Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Casdozokitug by Coherus BioSciences for Solid Tumor: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Casdozokitug by Coherus BioSciences for Hepatocellular Carcinoma: Likelihood of Approval
Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Coherus BioSciences's Casdozokitug?
Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Hepatocellular Carcinoma. According to...
Risk adjusted net present value: What is the current valuation of Coherus BioSciences's Casdozokitug?
Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Squamous Non-Small Cell Lung...